Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

Dimitrios A Karagiannis1, Ioannis D Ladas2, Efstratios Parikakis1, Ilias Georgalas2, Athanasios Kotsolis2, Giorgos Amariotakis1, Vasileios Soumplis1, Panagiotis Mitropoulos11Ophthalmiatrio Eye Hospital of Athens, Athens, Greece; 2First Department of Ophthalmology, Medical School of Athens University...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dimitrios A Karagiannis, Ioannis D Ladas, Efstratios Parikakis, et al.
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Age related macular degeneration Bevacizumab Ranimizumab subretinal haemorrhage Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/5b4a909ac95b4d3da9972cb7c9110698
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5b4a909ac95b4d3da9972cb7c9110698
record_format	dspace
spelling	oai:doaj.org-article:5b4a909ac95b4d3da9972cb7c91106982021-12-02T00:36:25ZChanging from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?1178-1998https://doaj.org/article/5b4a909ac95b4d3da9972cb7c91106982009-11-01T00:00:00Zhttps://www.dovepress.com/changing-from-bevacizumab-to-ranibizumab-in-age-related-macular-degene-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Dimitrios A Karagiannis1, Ioannis D Ladas2, Efstratios Parikakis1, Ilias Georgalas2, Athanasios Kotsolis2, Giorgos Amariotakis1, Vasileios Soumplis1, Panagiotis Mitropoulos11Ophthalmiatrio Eye Hospital of Athens, Athens, Greece; 2First Department of Ophthalmology, Medical School of Athens University, General Hospital of Athens, Athens, GreeceObjective: To report our experiences in changing from intravitreal bevacizumab to ranibizumab in age-related macular degeneration (AMD).Design: Retrospective case series.Participants and methods: We retrospectively reviewed the records of 34 patients (36 eyes) who were treated with monthly injections of intravitreal bevacizumab for six months and then switched to monthly injections of ranibizumab for 12 months. Best-corrected visual acuity measurements (BCVA), contact lens biomicroscopy, optical coherence tomography (OCT), and fluorescein angiography were performed at the baseline examination and then monthly. Chi-square test was used for statistical analysis.Results: Following bevacizumab treatment, retinal thickness decreased (P = 0.033) while BCVA improved (P = 0.040). Changing from bevacizumab to ranibizumab resulted in a transient decrease in BCVA (P = 0.045) and an increase in retinal thickness (P = 0.042). In addition, three eyes presented with a large subretinal hemorrhage. However, final retinal thickness was better than the initial thickness and the value following the bevacizumab course. No major ocular or systemic side effects were noted.Conclusions: Ranibizumab was clinically effective in the long term but the change of treatment from bevacizumab to a half-size molecule with less half-life in the vitreous such as ranibizumab contributed to a transient “instability” in the eye which may have triggered the large subretinal hemorrhage. There is insufficient experience reported in the literature in switching from one agent to another. A prospective study with controls is necessary to determine whether it is safe to change from one medication to another.Keywords: age-related macular degeneration, bevacizumab, ranibizumab, subretinal hemorrhageDimitrios A KaragiannisIoannis D LadasEfstratios Parikakiset al.Dove Medical PressarticleAge related macular degenerationBevacizumabRanimizumabsubretinal haemorrhageGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 4, Pp 457-461 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Age related macular degeneration Bevacizumab Ranimizumab subretinal haemorrhage Geriatrics RC952-954.6
spellingShingle	Age related macular degeneration Bevacizumab Ranimizumab subretinal haemorrhage Geriatrics RC952-954.6 Dimitrios A Karagiannis Ioannis D Ladas Efstratios Parikakis et al. Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
description	Dimitrios A Karagiannis1, Ioannis D Ladas2, Efstratios Parikakis1, Ilias Georgalas2, Athanasios Kotsolis2, Giorgos Amariotakis1, Vasileios Soumplis1, Panagiotis Mitropoulos11Ophthalmiatrio Eye Hospital of Athens, Athens, Greece; 2First Department of Ophthalmology, Medical School of Athens University, General Hospital of Athens, Athens, GreeceObjective: To report our experiences in changing from intravitreal bevacizumab to ranibizumab in age-related macular degeneration (AMD).Design: Retrospective case series.Participants and methods: We retrospectively reviewed the records of 34 patients (36 eyes) who were treated with monthly injections of intravitreal bevacizumab for six months and then switched to monthly injections of ranibizumab for 12 months. Best-corrected visual acuity measurements (BCVA), contact lens biomicroscopy, optical coherence tomography (OCT), and fluorescein angiography were performed at the baseline examination and then monthly. Chi-square test was used for statistical analysis.Results: Following bevacizumab treatment, retinal thickness decreased (P = 0.033) while BCVA improved (P = 0.040). Changing from bevacizumab to ranibizumab resulted in a transient decrease in BCVA (P = 0.045) and an increase in retinal thickness (P = 0.042). In addition, three eyes presented with a large subretinal hemorrhage. However, final retinal thickness was better than the initial thickness and the value following the bevacizumab course. No major ocular or systemic side effects were noted.Conclusions: Ranibizumab was clinically effective in the long term but the change of treatment from bevacizumab to a half-size molecule with less half-life in the vitreous such as ranibizumab contributed to a transient “instability” in the eye which may have triggered the large subretinal hemorrhage. There is insufficient experience reported in the literature in switching from one agent to another. A prospective study with controls is necessary to determine whether it is safe to change from one medication to another.Keywords: age-related macular degeneration, bevacizumab, ranibizumab, subretinal hemorrhage
format	article
author	Dimitrios A Karagiannis Ioannis D Ladas Efstratios Parikakis et al.
author_facet	Dimitrios A Karagiannis Ioannis D Ladas Efstratios Parikakis et al.
author_sort	Dimitrios A Karagiannis
title	Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
title_short	Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
title_full	Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
title_fullStr	Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
title_full_unstemmed	Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
title_sort	changing from bevacizumab to ranibizumab in age-related macular degeneration. is it safe?
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/5b4a909ac95b4d3da9972cb7c9110698
work_keys_str_mv	AT dimitriosakaragiannis changingfrombevacizumabtoranibizumabinagerelatedmaculardegenerationisitsafe AT ioannisdladas changingfrombevacizumabtoranibizumabinagerelatedmaculardegenerationisitsafe AT efstratiosparikakis changingfrombevacizumabtoranibizumabinagerelatedmaculardegenerationisitsafe AT etal changingfrombevacizumabtoranibizumabinagerelatedmaculardegenerationisitsafe
_version_	1718403620762812416

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

Ejemplares similares